Ursina R Teitelbaum MD
Professor of Clinical Medicine, Perelman School of Medicine
Join to View Full Profile
3400 convention Center BoulevardSouth Tower 10Philadelphia, PA 19104
Phone+1 215-662-6319
Fax+1 215-662-2432
Dr. Teitelbaum is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Ursina Teitelbaum is an oncologist in Philadelphia, PA and is affiliated with multiple hospitals in the area, including Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, and UPMC Presbyterian. She received her medical degree from University of Maryland School of Medicine and has been in practice 18 years. She also speaks multiple languages, including German and French. She is experienced in medical oncology, palliative medicine and geriatrics. Her subspecialty is gastrointestinal oncology.
Education & Training
University of ChicagoFellowship, Hematology and Medical Oncology, 2003 - 2005- University of ChicagoFellowship, Geriatric Medicine (Internal Medicine), 2002 - 2003
- University of ChicagoResidency, Internal Medicine, 1999 - 2002
University of Maryland School of MedicineClass of 1999
Certifications & Licensure
FL State Medical License 2026 - 2028
DE State Medical License 2025 - 2027
MD State Medical License 2025 - 2027
NJ State Medical License 2026 - 2027
PA State Medical License 2006 - 2026
IL State Medical License 1999 - 2008
American Board of Internal Medicine Hospice and Palliative Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012, 2014-2017
- CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2012, 2014-2017
Clinical Trials
- FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer Start of enrollment: 2010 Sep 01
- Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy Start of enrollment: 2011 Jul 01
Publications & Presentations
PubMed
- Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial.Kimberly J Perez, Andressa Dias Costa, Alexander Jordan, Thomas B Karasic, Dalia Elganainy
Nature Cancer. 2026-06-01 - Long-Term Outcomes of Patients With BRCA+ or PALB2+ Pancreatic Cancer Treated With Maintenance Rucaparib: A Secondary Analysis of a Nonrandomized Clinical Trial.Kim A Reiss, Mingyi Xia, Mwangala Akamandisa, Kurt D'Andrea, Brad Wubbenhorst
JAMA Oncology. 2026-06-01 - Consent, Concern, and Capacity: Factors Associated With Attitudes Toward Pharmacogenetic Testing Among Patients With Gastrointestinal Cancer.Arravinth Anantharajah, Raza Chaudhry, Victoria A Wittner, Mari Angelica S Cayabyab, Glenda Hoffecker
Clinical and Translational Science. 2026-01-01
Press Mentions
For Alex Trebek, the Toughest Question: Can He Face down Pancreatic Cancer?March 7th, 2019
Alex Trebek Has Stage 4 Pancreatic Cancer. Here's What That MeansMarch 7th, 2019
The Future of Pancreatic Cancer: A Conversation with Medical Oncologist Mark O'Hara, MDFebruary 11th, 2019
Other Languages
- German, French
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
